SAN LEANDRO, Calif.--(BUSINESS WIRE)--BioClin Therapeutics, Inc., a privately-held clinical stage drug development company developing a first-in-class anti-FGFR3 (fibroblast growth factor receptor 3) monoclonal antibody in areas of high unmet medical need, announced today the appointment of Scott D. Myers as chairman of Board of Directors.
Stephen Lau, Chief Executive Officer of BioClin, stated, “Scott’s addition adds important expertise and experience to the Board of Directors. Our company is entering a new phase of development and Scott’s experiences as a global, life sciences leader will be very valuable.”
Mr. Myers was most recently CEO, President and a Director of Seattle based, Cascadian Therapeutics (NASDAQ: CASC), an oncology company until it was acquired by Seattle Genetics (NASDAQ: SGEN) in March of 2018. Prior to Cascadian, Mr. Myers was CEO of Aerocrine AB, a medical device company based in Stockholm, Sweden and Morrisville, NC until it was acquired by Circassia, PLC in 2015. Prior to Aerocrine, Mr. Myers held senior commercial operation, general management and information management positions for UCB SA, a Belgium based biopharmaceutical company, and Johnson & Johnson.
Mr. Myers commented, “I believe BioClin’s product candidate for metastatic bladder cancer holds great promise to fulfill an unmet need and I look forward to working with Stephen and the rest of the board to help drive value for our key stakeholders including patients, providers, employees and shareholders.”
About BioClin Therapeutics, Inc.
BioClin Therapeutics, Inc. is a privately-held clinical stage biotechnology company developing biologics to address medical conditions in areas of high unmet need. The company is focused on FGFR3 (fibroblast growth factor receptor 3), a driver mutation in metastatic bladder cancer and potentially other cancers. The company’s lead program, B-701, is the only targeted biologic specific for FGFR3 in clinical development. BioClin has ongoing clinical studies in metastatic bladder cancer including B-701 monotherapy, and B-701 in combination with standard-of-care chemotherapy, as well as with pembrolizumab, an immune checkpoint inhibitor.
For more information, please visit BioClin’s website: www.bioclintherapeutics.com
This press release contains forward-looking statements about the business and prospects of BioClin Therapeutics, Inc., which involve risks and uncertainties, including, without limitation, statements about the timing and plans to conduct clinical trials of B-701 in mUC. These risks and uncertainties include, among others: timing of enrollment in and results of the clinical trials; safety of B-701 alone or in combination with other therapies; the content and timing of decisions by the U.S. Food and Drug Administration, the European Commission and other regulatory authorities concerning B-701. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs. The company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. BioClin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.